Vistagen Therapeutics, Inc. develops late clinical-stage biopharmaceutical programs based on nose-to-brain neurocircuitry and intranasal pherine product candidates. Company news centers on fasedienol nasal spray for the acute treatment of social anxiety disorder, including PALISADE Phase 3 study updates, and refisolone nasal spray for vasomotor symptoms due to menopause.
Recurring updates also cover FDA and IND communications, clinical data from psychiatric and neurological programs, fiscal results, cash-management actions, executive and board changes, and healthcare investor conference presentations. The company’s pipeline is described around investigational intranasal candidates for indications that include social anxiety disorder, major depressive disorder, and menopausal hot flashes.
SRX Global (SRXH) added an investment in Onconetix (ONCO) and updated shareholders on the liquidation of two portfolio holdings.
The holdings are Vistagen Therapeutics (VTGN) and Greenland Mines (GRML). SRX said it added Onconetix in anticipation of the closing of Onconetix's previously announced agreement to acquire Realbotix. Realbotix developed Vinci, an AI vision system that places cameras and tracking lenses inside robotic eyes. The system is described as detecting motion, recognizing returning users and identifying objects or colors.
Vistagen (VTGN) reported exploratory fasedienol findings in people with very severe social anxiety disorder from two placebo-controlled studies. Very severe social anxiety was defined as a baseline Liebowitz Social Anxiety Scale score of 95 or higher.
In a post-hoc analysis of the Phase 3 PALISADE-4 trial, this subgroup had significantly lower average anxiety scores during a public speaking challenge with fasedienol than with placebo, although the trial missed its primary endpoint in the full population. A prespecified subgroup analysis in a Phase 2a repeat-dose study found a significant improvement after one dose and a greater numerical improvement after a second dose given 10 minutes later.
Vistagen (VTGN) reported preliminary positive data from the open-label extension (OLE) portion of its Phase 3 PALISADE-4 study of fasedienol nasal spray for the acute treatment of social anxiety disorder.
In 322 adults using 3.2 µg fasedienol as needed, up to six times daily for up to 12 months, treatment was well-tolerated, with a 1.6% discontinuation rate due to adverse events and no discontinuations or serious adverse events attributed to fasedienol. More than 95% of treatment-emergent adverse events were mild or moderate; headache (18.0%), upper respiratory tract infection (9.9%), rhinorrhoea (7.1%), and oropharyngeal pain (5.3%) were the most common. No safety signals of concern were seen in labs, ECGs, exams, or vital signs.
Exploratory efficacy over four months showed clinically relevant improvements on the clinician-rated LSAS (mean improvement rising from 20.2 to 31.4 points; ≥20‑point responders increasing from 44% to 65%) and patient-reported SPIN (mean improvement rising from 10.5 to 14.9 points; ≥10‑point responders increasing from 45% to 59%). The company is preparing to meet with the FDA this quarter to discuss a proposed new registrational Phase 3 trial in social anxiety disorder.
Vistagen (VTGN) will present Phase 3 fasedienol nasal spray data showing a positive efficacy signal in public speaking challenge participants with very severe social anxiety disorder at Psych Congress in New Orleans on September 17–18, 2026.
The poster, number 230, is titled “Fasedienol Nasal Spray for Acute Treatment of Social Anxiety Disorder in Participants With Baseline LSAS Scores ≥95: Subgroup Analyses from Two Multi-center, Randomized, Placebo-controlled Public Speaking Challenge Trials.”
Vistagen (Nasdaq: VTGN) reported fiscal 2027 first quarter results for the period ended June 30, 2026, and provided a corporate update focused on its pherine pipeline. Revenue rose to $1.5 million, mainly from $1.2 million recognized upon expiration of an exclusive negotiation agreement with Fuji Pharma. R&D expense declined to $10.9 million from $11.7 million, and G&A fell to $3.9 million from $4.4 million, reducing net loss to $13.0 million from $15.1 million year over year.
Cash, cash equivalents, and marketable securities totaled $31.7 million, which the company believes will fund operations into 2027, but for less than one year from now. Clinically, Vistagen reported exploratory and post‑hoc analyses for fasedienol in social anxiety disorder, achieved ICH-recommended exposure levels, and is preparing for an FDA meeting on a potential registration-directed path. The FDA also issued a “Study May Proceed” letter for refisolone in menopausal hot flashes. The company appointed Angel S. Angelov, M.D., MBA, as Chief Medical Officer and Douglas J. Williamson, M.D., to its Board, and continued cost-management initiatives.
Vistagen (Nasdaq: VTGN) reported topline results from an exploratory Phase 2, three‑arm, randomized, double‑blind, placebo‑controlled study (N=61) of intranasal fasedienol for acute treatment of social anxiety disorder induced by a public speaking challenge. The trial compared repeat 3.2 µg dosing ten minutes apart, single 3.2 µg dosing, and placebo.
The study met its primary safety objective, with repeat dosing showing safety and tolerability comparable to single dosing and no new safety findings. Numerically greater reductions in subjective units of distress (SUDS) versus placebo were observed for pooled, repeat, and single‑dose fasedienol, though overall group differences were not statistically significant (p=0.2). In a prespecified very severe subgroup (baseline LSAS ≥95), pooled and single‑dose fasedienol showed nominally statistically significant SUDS improvements versus placebo (p=0.04 and p=0.05).
Responder rates on CGI‑I and PGI‑C were directionally higher for fasedienol than placebo, with repeat‑dose responder rates more than twice placebo overall and at least four times placebo in the very severe subgroup. A prespecified exploratory analysis of anticipatory anxiety showed larger SUDS reductions for pooled and repeat‑dose fasedienol versus placebo, with nominal statistical significance (p=0.03 and p=0.01). Vistagen indicated these data, together with prior Phase 2 and Phase 3 results, will inform discussions with the FDA about a potential registrational pathway for fasedienol.
SRX Global (NYSE American: SRXH) announced it has acquired a stake in Vistagen Therapeutics (NASDAQ: VTGN), described as a late clinical-stage biopharmaceutical company developing nose-to-brain intranasal product candidates, called pherines, to address neurocircuitry involved in neuroscience indications.
According to SRX Global, it views Vistagen shares as undervalued and is open to constructive engagement with Vistagen’s leadership team and Board of Directors to discuss ideas for unlocking shareholder value. SRX Global describes itself as an AI-driven investment platform that uses proprietary technology, data analytics, and disciplined capital allocation to invest in high-conviction operating companies, strategic assets, and technology-enabled opportunities across multiple sectors.
Vistagen (Nasdaq: VTGN) has appointed Douglas J. Williamson, MD, to its Board of Directors. Dr. Williamson brings nearly 30 years of leadership in neuroscience drug development, clinical research, and regulatory strategy, spanning early-stage studies through regulatory approval and commercialization.
According to Vistagen, Dr. Williamson is currently a CNS Drug Development Consultant and founder of Destiny Biopharm Consulting. His prior roles include Chief Medical Officer at QurAlis, Executive Vice President and Head of R&D at Acadia Pharmaceuticals, senior leadership positions at H. Lundbeck, Avadel Pharmaceuticals, Parexel, and contributions at Eli Lilly to the development and approval of multiple neuropsychiatric therapies. He previously served on the Board of Bright Minds Biosciences (Nasdaq: DRUG).
Vistagen (Nasdaq: VTGN) reported topline results from PALISADE-4, a Phase 3 public speaking challenge trial of intranasal fasedienol for social anxiety disorder. Fasedienol did not meet primary or secondary endpoints in the overall population but showed nominal statistical significance in a post-hoc very severe subgroup, with safety consistent with prior trials.
Vistagen plans to discuss with the FDA a potential registrational path centered on a single multi-dose Phase 3 trial using LSAS as the primary endpoint and confirmatory evidence from the PALISADE program. The company expects its cash resources to fund operations into 2027 and highlights a late clinical-stage intranasal pherine pipeline.
Vistagen (Nasdaq:VTGN) reported fiscal 2026 results and pipeline progress. Research and development expense was $55.0 million and general and administrative expense was $18.4 million, leading to a net loss of $69.7 million. Cash, cash equivalents, and marketable securities totaled $45.4 million, which Vistagen believes will fund operations into 2027.
The company completed randomized portions of key fasedienol trials in social anxiety disorder, reported preliminary positive open-label Phase 3 data, met ICH E1 exposure recommendations, and received FDA “Study May Proceed” clearance to advance refisolone for menopausal vasomotor symptoms.